<DOC>
	<DOCNO>NCT00935844</DOCNO>
	<brief_summary>This study conduct evaluate safety profile Maximum Tolerated Dose ( MTD ) TAK-901 adult patient advance solid tumor lymphoma . This study help identify recommended phase 2 dose infusion duration , describe pharmacokinetics TAK-901 .</brief_summary>
	<brief_title>Study TAK-901 Adults With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Each patient must meet follow criterion enrol study : ECOG performance status &lt; equal 2 . Diagnosis solid tumor malignancy lymphoma standard treatment longer effective . Have radiographically clinically evaluable tumor lymphoma . Measurable disease describe protocol . Suitable venous access studyrequired blood sampling . Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception abstain heterosexual intercourse . Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse . Voluntary write consent . Weigh least 45 kg . Recovered reversible effect prior antineoplastic therapy . Meet clinical laboratory value screen period specify protocol . Left ventricular ejection fraction ( LVEF ) &gt; equal 50 % echocardiogram multiple acquisition scan ( MUGA ) . Patients meet follow exclusion criterion enrol study : Diagnosis primary CNS malignancy carcinomatous meningitis . Patient symptomatic brain metastasis . Prior bone allogeneic bone marrow stem cell transplant . Prior radiotherapy involve &gt; equal 30 % hematopoietically active bone marrow , within 21 day start study drug . Systemic antineoplastic therapy within 28 day start study drug , except luteinizing hormonereleasinghormone ( LHRH ) agonist therapy . Exposure nitrosureas mitomycin C within 42 day start study drug . Treatment monoclonal antibody within 28 day start study drug . Known allergy hypersensitivity compound similar chemical composition TAK901 excipient , Captisol . Female patient lactate positive serum pregnancy test screen period positive serum pregnancy test screening period . Myocardial infarction within 6 month enrollment . Evidence current uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure , angina , electrocardiographic evidence acute ischemia active conduction system abnormality . Abnormalities 12lead electrocardiogram ( ECG ) specify protocol . Infection require systemic antiinfective therapy within 14 day start study drug . Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection . Diagnosed treat another malignancy within 2 year start study drug previously diagnose another malignancy evidence residual disease . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment . Treatment investigational product within 28 day first dose study drug . Systemic use strong CYP3A inhibitor inducer ( specify protocol ) within 14 day first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Lymphoma</keyword>
</DOC>